Cover Image

Impact of the Gastric Acid Suppressant Use on the Safety and Effectiveness of EGFR-TKIs: A Systematic Review and Meta-Analysis

Background The use of gastric acid suppressants (GASs) has an influence on the exposure of some epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and therefore may affect the effectiveness and safety of EGFR-TKIs. The impact of GASs, including proton pump inhibitors (PPIs) and...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xin Du (Author), Wei Liu (Author), Ken Chen (Author), Ziyu Wang (Author), Xinyi Li (Author), Li Yang (Author), Xiaohui Xie (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
by: Di Wu, et al.
Published: (2022)

Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond
by: Xin Li, et al.
Published: (2024)

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
by: Yujia Wang, et al.
Published: (2021)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
by: Dantong Sun, et al.
Published: (2020)

Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis
by: Yan Lu, et al.
Published: (2021)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
by: Si-Yang Maggie Liu, et al.
Published: (2023)

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
by: Xiaotong Song, et al.
Published: (2023)

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
by: Dantong Sun, et al.
Published: (2021)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
by: Yue Zeng, et al.
Published: (2022)

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer
by: Dehua Liao, et al.
Published: (2022)

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
by: Carmelo Laface, et al.
Published: (2023)

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities
by: Xiaohong Liu, et al.
Published: (2024)

A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma
by: Xue Han, et al.
Published: (2023)

Assessment of the Relationship Between Gastric-Acid Suppressants and the Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis
by: Karamali Kasiri, Associate, et al.
Published: (2023)

Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring
by: Lan Chen, et al.
Published: (2024)

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
by: Geunho Choi, et al.
Published: (2021)

Impact of Dose Reduction of Afatinib Used in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
by: Ziyu Wang, et al.
Published: (2021)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022)

Statin Gastroprotective Mechanisms Independent of Gastric Acid Suppression
by: Dilgash Abdullah, et al.
Published: (2023)

History and Pharmacological Mechanism of Gastric Acid-suppressive Drugs
by: Dong Han Yeom, et al.
Published: (2023)

Chebulagic acid suppresses gastric cancer by inhibiting the AURKA/β-catenin/Wnt pathway
by: Jing Zhao, et al.
Published: (2023)

Interventions for Preventing Cardiotoxicity in Breast Cancer Patients Receiving Trastuzumab: A Systemic Review and Bayesian Network Meta-Analysis
by: Xinyi Li, et al.
Published: (2021)

Lysophosphatidic Acid-Induced EGFR Transactivation Promotes Gastric Cancer Cell DNA Replication by Stabilizing Geminin in the S Phase
by: Haile Zhao, et al.
Published: (2021)

Acacetin exerts antitumor effects on gastric cancer by targeting EGFR
by: Guangtao Zhang, et al.
Published: (2023)

Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis
by: Zeyi Zheng, et al.
Published: (2023)

Piperine Attenuates Lithocholic Acid-Stimulated Interleukin-8 by Suppressing Src/EGFR and Reactive Oxygen Species in Human Colorectal Cancer Cells
by: Shinan Li, et al.
Published: (2022)

Efficacy of hyaluronic acid in the treatment of nasal inflammatory diseases: a systematic review and meta-analysis
by: Huixia Liu, et al.
Published: (2024)

Can the Combination of Famotidine and Prokinetics Have Additional Effects on Gastric Acid Suppression?
by: Yoon Jin Choi
Published: (2021)

Corrigendum: Efficacy of hyaluronic acid in the treatment of nasal inflammatory diseases: a systematic review and meta-analysis
by: Huixia Liu, et al.
Published: (2024)

IGFBP2 functions as an endogenous protector against hepatic steatosis via suppression of the EGFR-STAT3 pathway
by: Tianyu Zhai, et al.
Published: (2024)

Gallic acid suppresses the progression of triple-negative breast cancer HCC1806 cells via modulating PI3K/AKT/EGFR and MAPK signaling pathways
by: Si Lin, et al.
Published: (2022)

The Risk of QTc Prolongation in Non-Diabetic and Diabetic Patients Taking Tyrosine Kinase Inhibitors (TKIs)- A Patient Safety Project at a Private Oncology Practice
by: Zhongju Lu, et al.
Published: (2021)

Rabeprazole suppressed gastric intestinal metaplasia through activation of GPX4-mediated ferroptosis
by: Jing Xie, et al.
Published: (2024)

The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis
by: Xi Zhong, et al.
Published: (2020)

Acid-Suppressive Drugs and Risk of Fracture in Children and Young Adults: A Meta-Analysis of Observational Studies
by: Jiangbi Li, et al.
Published: (2021)

Gallic Acid Impedes Non-Small Cell Lung Cancer Progression via Suppression of EGFR-Dependent CARM1-PELP1 Complex
by: Wang D, et al.
Published: (2020)

Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors
by: Lianbao Ye, et al.
Published: (2019)

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis
by: Wei Chen, et al.
Published: (2023)

Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis
by: Huizhu Guo, et al.
Published: (2023)